Showing results (551-560 of 622) with videos related to

Sort By:
Pageof 63
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 4, 2024
Optimal [<sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain TrialGeraldine Gebhart, Marleen Keyaerts, Thomas Guiot, et al.
Molecular Ecology Resources|August 5, 2016
A large set of 26 new reference transcriptomes dedicated to comparative population genomics in crops and wild relativesGautier Sarah, Felix Homa, Stéphanie Pointet, et al.
European Journal of Cancer (Oxford, England : 1990)|April 16, 2022
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL studyMiguel Martín, Christoph Zielinski, Manuel Ruiz-Borrego, et al.
Bone|August 10, 2014
Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study)Agustí Barnadas, Luis Manso, Concepción de la Piedra, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2026
Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trialÁngel Guerrero-Zotano, Miguel Gil-Gil, Amy Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2025
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA TrialFederico Rojo, Clive R Taylor, Carlos Barrios, et al.
European Journal of Cancer (Oxford, England : 1990)|December 10, 2025
Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 studyManuel Ruiz Borrego, David Páez López-Bravo, Mireia Margelí Vila, et al.
Plos One|October 21, 2014
The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapyAngelo Gámez-Pozo, Ramón M Pérez Carrión, Luis Manso, et al.
Plos Genetics|May 23, 2017
Evolutionary forces affecting synonymous variations in plant genomesYves Clément, Gautier Sarah, Yan Holtz, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 28, 2024
Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR studyAlejandro Falcón González, Josefina Cruz Jurado, Elisenda Llabrés Valenti, et al.
Pageof 63